Clinical Trial

The Implementation and Impact of an Allergy De-Labeling Program in the Emergency Department

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Beta-lactams are the most common antibiotics prescribed to children, including penicillin and amoxicillin. They are usually more effective and have fewer side effects than other ty antibiotics. Some children can have reactions to these antibiotics that can be mistaken as an allergy, especially rashes that develop days to weeks later. In such cases, when children take the antibiotic again, they have no problem tolerating it; this is called "delabeling an allergy" with an "oral challenge". Based on our experience with a similar program among inpatients, we are implementing and evaluating an allergy delabeling program for children in the SickKids ED, with the hope and intent to delabel most children of their "allergies" using an oral challenge.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-02-06; most recent amendment 2026-04-30.
Status change: Enrolling by Invitation → Active, Not Recruiting 2026-04-30
Status change: Active, Not Recruiting → Enrolling by Invitation 2025-11-20
Trial Details
NCT Number NCT06823154
Lead Sponsor The Hospital for Sick Children
Conditions Allergy Amoxicillin, Beta-lactam Allergy Labels
Enrollment 500 participants
Start Date 2023-11-27
Primary Completion 2026-02-17 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-07